Boehringer Ingelheim GmbH
+49 6132 77 8271
Companies to advance 11beta-HSD1 inhibitors for diabetes and potentially other
metabolic syndrome related indications
Fort Washington, Pennsylvania and Ingelheim, Germany – October 15, 2007–
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have
established a major collaboration to develop and commercialize 11beta-HSD1 inhibitors.
Compounds which inhibit 11beta-HSD1, an enzyme involved in cortisol production, may
have utility in the treatment of diabetes and metabolic syndrome related diseases, including
obesity, dyslipidemia and hypertension. The companies will combine their respective
11beta-HSD1 programs and work together to identify and advance candidates for clinical
Under the terms of the collaboration agreement, Vitae will receive $36.5 million in upfront
and near-term payments from Boehringer Ingelheim, comprising upfront cash, an equity
investment in Vitae and researchfunding. In addition, Vitae will be eligible to receive up
to $300 million milestone payments based on the achievement of development, regulatory
and commercial program goals.
Further milestone payments may be achieved with additional compounds and/or additional
approved indications. Vitae will receive royaltypayments from Boehringer Ingelheim on
all potential future product sales. Further financial details were not disclosed.
Boehringer Ingelheim will lead development and commercialization of products. In
addition, Vitae will have the right to develop products independently for certain indications.
“Diabetes is a rapidly growing concern worldwide, and the need for safe and effective
medicines that will help diabetic patients has never been greater. Vitae has discovered and
rapidly advanced novel, highly potent 11beta-HSD1 inhibitors in multiple series over the
past 20 months using its unique structure-based drug design technology CONTOUR™,”
said Jeffrey Hatfield, CEO of Vitae. “Our collaboration withBoehringer Ingelheim and its
dynamic team of metabolic disease experts provides the resource and capabilities to drive
this program into the clinic. Boehringer Ingelheim clearly shares our passion and
excitement for this new therapeutic target, and we look forward to working together with
the aim to deliver on the target’s full potential.”
Dr Andreas Barner, Vice-Chairman of the Board of Managing Directors and Head of
Corporate Board Division Pharma Research, Development and Medicine of Boehringer
Ingelheim, added, that “Boehringer Ingelheim looks forward to collaborate with Vitae to
complement its own diabetes pipeline development activities by combining resources on
this exciting target. We are using our overall expertise in metabolic research, drug
development and commercialisation to strengthen our current metabolic portfolio and lead
to advances for patients suffering fromthese serious debilitating diseases."
About 11beta HSD1 Inhibition
11beta-HSD1 is an enzyme that converts the biologically inactive steroid cortisone into the
active hormone cortisol. Cortisol is known to act as a functional antagonist of insulin
activity in multiple target tissues, including liver, muscle and adipose tissues. Overexpression of 11beta-HSD-1 in murine adipose tissue leads to a metabolic syndrome-like
phenotype, including increased central obesity, hypertension, impaired glucose tolerance,
and hypertriglyceridemia. In contrast, 11beta-HSD1 knockout (KO) mice resist visceral
obesity and diabetes through improved liver and adipose tissue function, consistent with the
beneficial effects of selective enzyme inhibition. Early clinical evidence has shown that
inhibiting 11beta-HSD1 can reduce glucose and lipids in diabetic patients. These data
indicate that elevated adipose or liver 11beta-HSD1 is detrimental for metabolic control.
Pharmacological inhibition of 11beta-HSD1 represents an attractive therapeutic target for
diabetes and treating cardiovascular effects associated with the metabolic syndrome.
Nearly 30 million adults suffer from Type 2 diabetes in the United States; 194 million
worldwide. That number is expected to nearly double in the next twenty years. One in four
Americans suffer from obesity/diabetes; in addition, over 40 million people are diagnosed in the pre-diabetic state. An aging population, sedentary lifestyle and rapidly growing
incidence of obesity are all contributing to the dramatic rise in prevalence of diabetes, of
which over 90% have Type 2 diabetes. The current U.S. market exceeds $10 billion, and is
predicted to grow to $45 billion by 2020.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is an emerging pharmaceutical company dedicated to the discovery
and development of innovative drugs, with a unique and powerful structure-based drug
design engine and a rapidly maturing portfolio of high value discovery programs. Vitae’s
goal is to discover, develop and commercialize innovative new medicines, alone and in
partnership, that will be best-in-class in important therapeutic areas such as cardiovascular
and metabolic disease, inflammation and CNS.Vitae Pharmaceuticals is financed by
leading corporate and venture capital investors and is headquartered in Fort Washington,
Pennsylvania. For additional information, please visit the company’s website,
The Boehringer Ingelheim Group is one ofthe world’s 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates
in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned
company has been committed to researching, developing, manufacturing and marketing
novel products of high therapeutic value for human and veterinary medicine.
In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one
fifth of net sales in its largest business segment Prescription Medicines on research and
development. For more information, please visit www.boehringer-ingelheim.com
# # #